New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
08:13 EDTMRTXMirati Therapeutic' mocetinostat granted ODD by FDA as treatment for MDS
Mirati Therapeutics announced that mocetinostat, the company's spectrum selective HDAC inhibitor, has been granted Orphan Drug Designation, or ODD, by the FDA as a treatment for myelodysplastic syndrome, or MDS. Mocetinostat is being developed in Phase 2 clinical studies in combination with Vidaza as a treatment for intermediate and high-risk MDS, as well as a single agent treatment in patients with diffuse large B-cell lymphoma and bladder cancer targeting specific genetic mutations in histone acetylation that increase the likelihood of response in tumor cells.
News For MRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 10, 2014
08:09 EDTMRTXMirati Therapeutics reports Q3 EPS (72c), consensus (76c)

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use